Comparison of the effectiveness of first- and second-line canakinumab therapy in pediatric colchicine-resistant familial Mediterranean fever: a real-world study

Comparative data on first-line versus second-line canakinumab following anakinra in pediatric colchicine-resistant familial Mediterranean fever (crFMF) are lacking. We compared effectiveness, flare characteristics, and flare-free survival between treatment sequences. This retrospective single-center cohort study included 89 pediatric patients with crFMF carrying biallelic pathogenic exon 10 Mediterranean Fever gene (MEFV) variants who received canakinumab for at least 6 months, either as first-line therapy (n = 48) or following anakinra (n = 41). Canakinumab significantly reduced median Pras Disease Severity Score from 8 to 6 and International Severity Scoring System for familial Mediterranean fever from 4 to 1 (both p < 0.001). Patients receiving first-line canakinumab had fewer attacks during the first 6 months (p = 0.014), lower early flare rates (2.1% vs 17.1%; p = 0.022), and a longer time to first flare (14 vs 10 months; p = 0.030) than those receiving second-line treatment. Flare-free survival tended to favor first-line treatment (35 vs 19 months; log-rank p = 0.087), while overall flare rates were similar. Most first flares occurred during dose-interval extension, particularly at 8 weeks. Canakinumab provided effective disease control regardless of treatment sequence. However, patients receiving first-line canakinumab experienced fewer early flares and a longer time to first flare compared with those receiving second-line treatment.

Authors

Publication Details

Journal
Figshare
Published
2026-11-14
DOI
https://doi.org/10.6084/m9.figshare.35011430
Primary Topic
Inflammasome and immune disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparison of the effectiveness of first- and second-line canakinumab therapy in pediatric colchicine-resistant familial Mediterranean fever: a real-world study

Sıla Atamyıldız Uçar, Eray Tunce, Neslihan Kara Çanlıoğlu, Betül Sözeri
Figshare
Inflammasome and immune disorders
article

Comparison of the effectiveness of first- and second-line canakinumab therapy in pediatric colchicine-resistant familial Mediterranean fever: a real-world study

Sıla Atamyıldız Uçar, Eray Tunce, Neslihan Kara Çanlıoğlu, Betül Sözeri
article en

Abstract

Comparative data on first-line versus second-line canakinumab following anakinra in pediatric colchicine-resistant familial Mediterranean fever (crFMF) are lacking. We compared effectiveness, flare characteristics, and flare-free survival between treatment sequences. This retrospective single-center cohort study included 89 pediatric patients with crFMF carrying biallelic pathogenic exon 10 Mediterranean Fever gene (MEFV) variants who received canakinumab for at least 6 months, either as first-line therapy (n = 48) or following anakinra (n = 41). Canakinumab significantly reduced median Pras Disease Severity Score from 8 to 6 and International Severity Scoring System for familial Mediterranean fever from 4 to 1 (both p < 0.001). Patients receiving first-line canakinumab had fewer attacks during the first 6 months (p = 0.014), lower early flare rates (2.1% vs 17.1%; p = 0.022), and a longer time to first flare (14 vs 10 months; p = 0.030) than those receiving second-line treatment. Flare-free survival tended to favor first-line treatment (35 vs 19 months; log-rank p = 0.087), while overall flare rates were similar. Most first flares occurred during dose-interval extension, particularly at 8 weeks. Canakinumab provided effective disease control regardless of treatment sequence. However, patients receiving first-line canakinumab experienced fewer early flares and a longer time to first flare compared with those receiving second-line treatment.

Figshare
Inflammasome and immune disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon